Buffalo Hump Liposuction: The Upper-Back Fat Pad That Needs a Lab Result Before It Needs a Cannula

Buffalo hump liposuction is one of the smaller procedures on the body-contouring menu and one of the more misunderstood. The target is the dorsocervical fat pad, the deposit that sits over the top of the spine where the neck meets the upper back. The pitch is compact: local anesthesia, one or two incisions the width of a pencil, thirty to sixty minutes of suction, a foam pad and a garment, and a neckline that lies flat in photographs. On short-form video the before-and-after is a single profile shot, which is why the procedure has found an audience it did not have a decade ago.

What the profile shot cannot show is why the fat is there. The dorsocervical pad is unusual among liposuction targets because it is a named physical sign. Medical students learn it as a feature of Cushing's syndrome, the state of cortisol excess, and as one of the fat redistributions produced by older HIV drug regimens. It enlarges with ordinary weight gain, it appears in a rare alcohol-associated lipomatosis, and it is routinely confused with a curved thoracic spine that has nothing to do with fat. A cannula addresses exactly one of those explanations.

That is the argument of this piece. The surgery itself is modest and reasonably safe in trained hands. The decision to have it is where the risk lives, because the hump is a sign before it is a shape, and a clinic that quotes a price after a pinch and a photograph has skipped the part of the visit that determines whether the result will last, whether the patient has an untreated disease, and whether the thing being suctioned is fat at all.

What a buffalo hump is, and what it is not

The short answer: a buffalo hump is a localized deposit of subcutaneous fat over the dorsocervical region at the base of the back of the neck, and it is a different problem from the bony or postural hump of kyphosis that gets called a dowager's hump, even though both are marketed under the same word.

The anatomy is simple. The pad sits between the skin and the fascia over the trapezius and nuchal ligament, roughly at the level of the seventh cervical and first thoracic vertebrae, the bony bump anyone can feel at the base of their own neck. It is ordinary subcutaneous fat, but denser and more fibrous than the fat of the abdomen or thighs, laced with septa that tether the skin to the tissue beneath. That fibrous quality matters later, because it changes how the fat behaves under a cannula.

Everything else that gets called a hump is a different structure. Thoracic hyperkyphosis, the exaggerated forward curve of the upper spine, is the most common confusion: in older adults it is frequently the result of osteoporotic vertebral compression fractures, and population studies summarized by Kado and colleagues put the prevalence of hyperkyphosis somewhere between a fifth and two fifths of people over sixty. That hump is bone. Forward-head posture, the so-called tech neck, is a hump of alignment, visible in profile and gone when the shoulders are pulled back. A lipoma is a single encapsulated mass, sometimes in the same spot, that comes out as a lump rather than as suction. Short-form video files all four under "hump" and sells one fix.

The way to tell them apart takes two minutes. Fat can be pinched between finger and thumb and rolled; a bony curve cannot. A hump that changes with posture is posture. A hump that is firm, fixed, and continuous with the spine below it wants a lateral spine X-ray, not a consultation. Any surgeon who books a suction case without doing that pinch, and without asking how the hump looks when the patient stands straight, has not yet established that there is anything to suction.

Why the workup comes before the cannula

The short answer: the dorsocervical fat pad is a textbook sign of cortisol excess and of drug-associated lipodystrophy, so suctioning it without ruling out those causes treats the silhouette while the disease, and the fat's reason for being there, continue.

Start with cortisol. Cushing's syndrome is the state of prolonged glucocorticoid excess, and the fat pad at the back of the neck is one of its classic findings alongside a rounded face, central weight gain, thin skin, and bruising. The endogenous version, from a pituitary or adrenal source, is rare: incidence is measured in a few cases per million people per year. The iatrogenic version is not rare at all, because prednisone and its relatives are among the most prescribed drugs in medicine, taken for asthma, autoimmune disease, transplant maintenance, and a dozen other conditions, and a patient on long-term steroids can grow a hump in months. A surgeon who does not take a drug history is guessing.

The Endocrine Society's clinical practice guideline on the diagnosis of Cushing's syndrome, published by Nieman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2008, is the reference document, and it is useful precisely because it is honest about specificity. It recommends screening with one of three tests: a 24-hour urine cortisol, a late-night salivary cortisol, or a one-milligram overnight dexamethasone suppression test. It also notes which features discriminate. Facial plethora, proximal muscle weakness, wide purple stretch marks, and easy bruising point toward the diagnosis. The dorsocervical fat pad, by itself, does not, because it is common in ordinary weight gain; fullness above the collarbones is a more specific sign than fullness at the nape. So not every hump is a hormone problem. But a hump plus any of the discriminating features is an endocrinology referral, and the referral costs a blood draw and a saliva tube. The suction costs several thousand dollars and does nothing for the cortisol.

The second cause is HIV-associated lipodystrophy. Older antiretroviral regimens, particularly stavudine and the first-generation protease inhibitors, produced a characteristic redistribution: fat loss in the face and limbs, fat gain in the abdomen and at the dorsocervical pad. Modern regimens do this much less, but the population treated in the late 1990s and 2000s still carries the result, and the buffalo hump in that setting is among the most published indications for the operation. Wolfort and colleagues described suction lipectomy for protease-inhibitor-associated fat in Plastic and Reconstructive Surgery in 1999, and the case series that followed reported a real recurrence rate when the metabolic picture did not change. Tesamorelin, approved by the FDA in 2010, is the only drug labeled for HIV lipodystrophy fat, and its label covers excess abdominal fat, not the hump.

The third, rarer cause is multiple symmetric lipomatosis, also called Madelung's disease or Launois-Bensaude syndrome: unencapsulated, infiltrative fat around the neck, shoulders, and upper back, seen mostly in men with heavy alcohol use. That fat has no boundaries, suction alone recurs, and open excision is usually the operation. The surgeon who has not asked about drinking has missed it. And in the most common scenario of all, simple weight gain, the pad is a fraction of total body fat, which means the conversation belongs alongside the one in the piece on GLP-1 drugs before surgery: a hump that shrinks by half on medically supervised weight loss is a different surgical target from the one first photographed.

"

A buffalo hump is a sign before it is a shape. Suction removes the shape. Only the workup finds out whether the sign was trying to say something.

"

How buffalo hump liposuction is actually done

The short answer: it is a small-volume liposuction of dense, fibrous fat, usually under tumescent local anesthesia with or without sedation, through one or two small incisions, often with ultrasound or power assistance because a standard cannula struggles in this tissue, and occasionally by open excision when the fat is too fibrous or the skin too loose to suction.

The patient lies prone or on the side. The surgeon infiltrates the pad with tumescent solution, dilute lidocaine with epinephrine, which numbs the area, shrinks the vessels, and firms the fat for the cannula; because the volumes are small the total lidocaine dose sits comfortably under the limits discussed in the piece on lidocaine toxicity, which is one reason the procedure is so often done awake. Prone positioning under deep sedation raises airway questions that an awake patient does not, and most surgeons prefer local with, at most, oral or light intravenous sedation.

Then the cannula. This is where the fibrous character of the pad shows itself. The septa that anchor skin to fascia resist a conventional suction cannula, the fat comes out slowly and unevenly, and the surgeon works harder to get a smooth result than in the abdomen. Ultrasound-assisted devices, which emulsify fat before suction, and power-assisted cannulas that vibrate through fibrous tissue both have a natural place here, and the trade-offs laid out in the comparison of VASER and traditional liposuction apply directly. Volumes are modest, often a few hundred milliliters, and the technical challenge is not how much comes out but the feathering at the edges, where the pad meets the slopes of the trapezius and the flat of the upper back. A hump that is removed but not blended leaves a shelf; a hump that is chased into the midline over the spinous processes leaves a divot.

What sits underneath is reassuring. The spinous processes, the nuchal ligament, and the trapezius are robust, there are no major vessels in the superficial plane, and the deep cervical structures are well protected by muscle. The dangerous-anatomy problem that governs facial procedures is largely absent here. The contour problem is not, and neither is the skin problem: an older patient, or one with a large long-standing hump, may find that the skin does not retract after the fat is gone, leaving a loose fold at the nape. For those patients, for Madelung's disease, and for fibrous recurrences, open excision through a horizontal incision at the back of the neck removes fat and skin together. That incision heals in one of the body's high-tension, high-risk regions for thick or raised scars, which is a real cost and belongs in the consultation.

What comes back, and what can go wrong

The short answer: the two signature problems are recurrence when the underlying cause was never addressed and contour deformity from uneven work in fibrous fat, with seroma, prolonged swelling, numbness at the nape, and thick scarring after open excision as the supporting cast.

Recurrence first. Fat cells removed by suction do not regenerate, but the cells left behind can enlarge, and the general biology in the piece on whether fat comes back after liposuction applies with a specific twist here. If cortisol excess is ongoing, whether from an untreated tumor or a prednisone prescription that cannot be stopped, the remaining pad grows and the hump returns, which is why the case reports of suction in Cushing's patients read as cautionary tales. In the HIV series, recurrence is reported in a meaningful share of patients and tracks with the metabolic picture rather than the surgery. In simple weight gain with stable weight afterward, the result is durable. The result, in other words, is only as permanent as the reason for the fat.

Contour second. Because the pad is fibrous and small, the margin for error is narrow. Over-resection at the midline produces a groove over the spine that is visible from behind and difficult to correct, since filling it means grafting fat into the very tissue that resisted removal. Under-resection at the edges produces a residual ridge. Asymmetry between the two sides of the neck is common enough to be a named complaint. These are not dangerous. They are permanent and they are on the back of the neck, which the patient sees only in photographs and in other people's expressions.

Then the routine list. The pad is a dependent, mobile area with new dead space after suction, and fluid collections are frequent; the management described in the piece on seromas applies, complicated by the fact that a garment does not fit the nape well. Most surgeons use shaped foam and tape rather than a standard garment, and the evidence question raised in the review of compression garments is at least as open here as elsewhere. Swelling persists for weeks, because the fibrous tissue holds fluid. Numbness over the nape from bruised cutaneous nerve branches is common and usually resolves. Infection and bleeding are rare. And the complication that does not appear on any consent form is the missed diagnosis: the patient whose hump was the one visible feature of a disease that went on being untreated after the hump was gone.

The non-surgical menu and the insurance question

The short answer: weight loss, including medically supervised GLP-1 therapy, shrinks the pad roughly in proportion to overall fat loss; no injectable or device is approved specifically for the dorsocervical pad; and insurers sometimes cover removal when the hump causes documented pain, limits neck motion, or belongs to a diagnosed lipodystrophy, but the case has to be built.

The non-surgical options are mostly borrowed from other body parts. Deoxycholic acid injection is approved by the FDA for fat under the chin and nowhere else; its use on the hump is reported, but the volume of drug a hump requires, the inflammation each session produces, and the fibrous tissue's resistance make it slow and expensive. Cryolipolysis devices carry clearances that include back fat, but the dorsocervical pad is a small, curved, fibrous target that flat applicators fit poorly, and the published evidence for that specific site is thin. Tesamorelin, as noted, is labeled for abdominal fat in HIV lipodystrophy. Treating the cause is the non-surgical option with the strongest evidence: successful treatment of Cushing's syndrome, or a steroid taper where the underlying disease allows one, reduces the pad over months without a cannula. And weight loss works on the hump as it works on the rest of the body, which is why the pad is increasingly appearing in the GLP-1 before-and-after literature, with the caveat that a fibrous residual often remains after the fat has gone.

Coverage is the question patients ask last and should ask first. Insurers treat removal of the dorsocervical pad as cosmetic by default and reconstructive by exception. The exceptions that have succeeded involve documented functional problems: chronic pain or headaches attributed to the hump, restricted neck extension, inability to lie flat or wear a helmet or collar for work, skin breakdown in the fold, or a diagnosed lipodystrophy with a supporting letter from an endocrinologist or infectious disease physician. Coverage for HIV-associated lipodystrophy varies by plan and by state, and some states have mandated it. The paperwork is tedious and the denial rate is high, but the alternative is self-pay for a procedure the patient may have a medical claim to. Anyone told "insurance never covers this" should ask who tried.

The honest summary

The dorsocervical fat pad is a physical sign before it is a cosmetic target. It enlarges with ordinary weight gain, which is the common story, but it is also a classic feature of cortisol excess, whether from a rare pituitary or adrenal tumor or from the very common prednisone prescription, a hallmark of older HIV drug regimens, and a component of an alcohol-associated lipomatosis that suction cannot cure. It is also routinely confused with a curved spine, which is bone, and with posture, which is neither. The workup is not elaborate: a drug and alcohol history, a pinch, a look at the patient standing straight, and, where the face, the skin, or the muscles suggest it, one of the three screening tests in the Endocrine Society guideline. The surgery, when it is the right answer, is a small awake liposuction of fibrous fat that rewards ultrasound or power assistance and punishes careless edges, with seroma, swelling, and contour irregularity as the ordinary risks and a thick scar as the price of open excision. The result lasts as long as the reason for the fat is gone, which is why it is durable after stable weight loss and unreliable in untreated Cushing's or unchanged lipodystrophy. The decision points are not the price or the downtime. They are whether anyone has asked why the fat is there, whether the hump is fat at all, and what the surgeon expects to happen to the result when the patient's weight or medication changes. If the clinic cannot answer those three questions, it has quoted a procedure without making a diagnosis, and the patient is about to pay to remove a symptom.